Advisory meeting with the European Medicines Agency

NextCell Pharma AB (“NextCell” or “the Company”) announces that a scientific advisory meeting with the European Medicines Agency (EMA) has been held regarding ProTrans and the path forward to a possible market approval. The focus was the design of the phase III study ProTrans-3, which NextCell intends to submit an application for later this year.Preparations for ProTrans-3 are progressing according to plan and the advisory meeting with EMA’s Scientific Advisory Working Party (SAWP) is an important milestone. The intended trial Principal Investigator, Professor Per-Ola Carlsson, participated